benchmarking

基准
  • 文章类型: Journal Article
    医疗保健提供者减少阿片类药物处方可以降低患者阿片类药物依赖的风险。同行比较已被证明会影响提供者的处方习惯,尽管它对阿片类药物处方的影响主要在急诊科进行了研究。
    这项研究的目的是描述企业范围内阿片类药物记分卡的开发,其实现的架构,并计划对其影响进行未来研究。
    使用作者基于企业供应商的电子健康记录生成的数据,企业分析软件,和来自一群专门的信息学家的专业知识,医师,和分析师,作者开发了阿片类药物记分卡,每季度通过电子邮件向我们机构的所有阿片类药物处方者发放.这些记分卡根据已建立的指标将提供者的阿片类药物处方习惯与整个企业专业内的同行进行比较。
    在本研究完成时,在截至2021年9月的5个季度中,2034家提供商至少收到了1张记分卡。泊松回归显示,阿片类药物处方季度减少1.6%,和卡方分析显示,用药时间超过5天的处方比例减少,吗啡等效日剂量>50。
    据我们所知,这是该量表在文献中首次发表的高质量基于证据的指标的同行比较工作.通过共享这个设计度量和分发过程的过程,作者希望通过同行比较来影响其他卫生系统,以试图遏制阿片类药物大流行。未来的研究检查这种干预措施的效果可以证明阿片类药物处方的显着减少,因此有可能降低个体患者向阿片类药物使用障碍的进展,并降低相关的发病率和死亡率风险.
    UNASSIGNED: Reductions in opioid prescribing by health care providers can lead to a decreased risk of opioid dependence in patients. Peer comparison has been demonstrated to impact providers\' prescribing habits, though its effect on opioid prescribing has predominantly been studied in the emergency department setting.
    UNASSIGNED: The purpose of this study is to describe the development of an enterprise-wide opioid scorecard, the architecture of its implementation, and plans for future research on its effects.
    UNASSIGNED: Using data generated by the author\'s enterprise vendor-based electronic health record, the enterprise analytics software, and expertise from a dedicated group of informaticists, physicians, and analysts, the authors developed an opioid scorecard that was released on a quarterly basis via email to all opioid prescribers at our institution. These scorecards compare providers\' opioid prescribing habits on the basis of established metrics to those of their peers within their specialty throughout the enterprise.
    UNASSIGNED: At the time of this study\'s completion, 2034 providers have received at least 1 scorecard over a 5-quarter period ending in September 2021. Poisson regression demonstrated a 1.6% quarterly reduction in opioid prescribing, and chi-square analysis demonstrated pre-post reductions in the proportion of prescriptions longer than 5 days\' duration and a morphine equivalent daily dose of >50.
    UNASSIGNED: To our knowledge, this is the first peer comparison effort with high-quality evidence-based metrics of this scale published in the literature. By sharing this process for designing the metrics and the process of distribution, the authors hope to influence other health systems to attempt to curb the opioid pandemic through peer comparison. Future research examining the effects of this intervention could demonstrate significant reductions in opioid prescribing, thus potentially reducing the progression of individual patients to opioid use disorder and the associated increased risk of morbidity and mortality.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:基于多组学数据的预测建模,其中包含了同一患者的几种类型的组学数据,已经显示出优于单组学预测建模的潜力。该领域的大多数研究都集中在合并多种数据类型,尽管购买它们的复杂性和成本。普遍的假设是,增加数据类型的数量必然会提高预测性能。然而,信息较少或冗余的数据类型的集成可能会阻碍这种性能。因此,确定能够增强预测性能的最有效的组学数据类型组合对于经济高效且准确的预测至关重要。
    方法:在本研究中,我们系统地评估了所有31种可能组合的预测性能,包括五种基因组数据类型中的至少一种(mRNA,miRNA,甲基化,DNAseq,和拷贝数变异)使用14个癌症数据集,具有右删失的生存结果,可从TCGA数据库公开获得。我们在每个模型中都采用了各种预测方法和加权的临床数据,以利用它们的预测重要性。Harrell的C指数和综合Brier评分被用作绩效指标。为了评估我们发现的稳健性,我们在包含的数据集级别进行了自举分析.对关键结果进行了统计检验,限制测试的数量,以确保低风险的假阳性。
    结果:与预期相反,我们发现,对于大多数癌症类型,仅使用mRNA数据或mRNA和miRNA数据的组合就足够了.对于某些癌症类型,额外纳入甲基化数据可改善预测结果.远远没有提高性能,引入更多数据类型通常会导致性能下降,这两种绩效指标之间的差异。
    结论:我们的发现挑战了普遍的观点,即在多组生存预测中结合多种组学数据类型可提高预测性能。因此,应该重新考虑在多组学预测中纳入尽可能多的数据类型的广泛方法,以避免次优的预测结果和不必要的支出.
    BACKGROUND: Predictive modeling based on multi-omics data, which incorporates several types of omics data for the same patients, has shown potential to outperform single-omics predictive modeling. Most research in this domain focuses on incorporating numerous data types, despite the complexity and cost of acquiring them. The prevailing assumption is that increasing the number of data types necessarily improves predictive performance. However, the integration of less informative or redundant data types could potentially hinder this performance. Therefore, identifying the most effective combinations of omics data types that enhance predictive performance is critical for cost-effective and accurate predictions.
    METHODS: In this study, we systematically evaluated the predictive performance of all 31 possible combinations including at least one of five genomic data types (mRNA, miRNA, methylation, DNAseq, and copy number variation) using 14 cancer datasets with right-censored survival outcomes, publicly available from the TCGA database. We employed various prediction methods and up-weighted clinical data in every model to leverage their predictive importance. Harrell\'s C-index and the integrated Brier Score were used as performance measures. To assess the robustness of our findings, we performed a bootstrap analysis at the level of the included datasets. Statistical testing was conducted for key results, limiting the number of tests to ensure a low risk of false positives.
    RESULTS: Contrary to expectations, we found that using only mRNA data or a combination of mRNA and miRNA data was sufficient for most cancer types. For some cancer types, the additional inclusion of methylation data led to improved prediction results. Far from enhancing performance, the introduction of more data types most often resulted in a decline in performance, which varied between the two performance measures.
    CONCLUSIONS: Our findings challenge the prevailing notion that combining multiple omics data types in multi-omics survival prediction improves predictive performance. Thus, the widespread approach in multi-omics prediction of incorporating as many data types as possible should be reconsidered to avoid suboptimal prediction results and unnecessary expenditure.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    对于肝细胞癌(HCC),N-糖基化已被证明广泛参与疾病的各个方面,包括发展,转移,亚型,诊断和预后。常见的做法是在癌症发生的原位发现生物标志物(即,癌症vs.相邻组织)由于非侵袭性,尚未在血清中进行临床监测。本研究以肝癌患者常见差异组织和血清N-糖蛋白的N-糖蛋白质组学表征为基准。来自相同患者的匹配组织和血清样品中的差异N-糖基化在完整的N-糖肽分子水平上进行了定量表征。发现了29种常见的N-糖蛋白。进行亚细胞定位分析以确认组织原创性。分泌的N-糖蛋白APOH上调,和跨膜和细胞内N-糖蛋白,包括OSMR,GAT2、CSF-1和MAGI3下调。
    For hepatocellular carcinoma (HCC), N-glycosylation has been proved to be widely involved in various aspects of the disease, including development, metastasis, subtyping, diagnosis and prognosis. The common practice is to discover biomarkers in situ of cancer occurrence (i.e., cancer vs. adjacent tissues) yet to clinically monitor in sera because of non-invasiveness. This study benchmarks N-glycoproteomics characterization of common differential tissue and serum N-glycoproteins of patients with HCC. Differential N-glycosylation in matched tissue and serum samples from the same patients were quantitatively characterized at the intact N-glycopeptide molecular level, and 29 common N-glycoproteins were found. Subcellular localization analysis was carried out to confirm the tissue originality. Secreted N-glycoprotein APOH was up-regulated, and transmembrane and intracellular N-glycoproteins including OSMR, GAT2, CSF-1 and MAGI3 were down-regulated.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    合成表格健康数据在医疗保健研究中起着至关重要的作用,解决隐私法规和公共可用数据集的稀缺性。这对于诊断和治疗的进步至关重要。最有前途的模型是基于变压器的大型语言模型(LLM)和生成对抗网络(GAN)。在本文中,我们将PythiaLLM缩放套件的LLM模型与从14M到1B的不同模型大小进行比较,针对参考GAN模型(CTGAN)。生成的合成数据用于训练用于分类任务的随机森林估计器,以对现实世界数据进行预测。我们的发现表明,随着参数数量的增加,LLM模型优于参考GAN模型。即使是最小的14M参数模型的性能也与GAN相当。此外,我们观察到训练数据集的大小与模型性能之间存在正相关。我们讨论含义,挑战,以及在实际中使用LLM模型进行合成表格数据生成的注意事项。
    Synthetic tabular health data plays a crucial role in healthcare research, addressing privacy regulations and the scarcity of publicly available datasets. This is essential for diagnostic and treatment advancements. Among the most promising models are transformer-based Large Language Models (LLMs) and Generative Adversarial Networks (GANs). In this paper, we compare LLM models of the Pythia LLM Scaling Suite with varying model sizes ranging from 14M to 1B, against a reference GAN model (CTGAN). The generated synthetic data are used to train random forest estimators for classification tasks to make predictions on the real-world data. Our findings indicate that as the number of parameters increases, LLM models outperform the reference GAN model. Even the smallest 14M parameter models perform comparably to GANs. Moreover, we observe a positive correlation between the size of the training dataset and model performance. We discuss implications, challenges, and considerations for the real-world usage of LLM models for synthetic tabular data generation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    孟德尔随机化(MR),它利用遗传变异作为工具变量(IV),作为使用遗传数据在表型之间进行因果推断的方法,已经越来越受欢迎。尽管已经努力放宽IV假设,并在存在由于混淆而导致的无效IV的情况下开发新的因果推断方法,MR方法在实际应用中的可靠性仍然不确定。而不是使用模拟数据集,我们进行了一项基准研究,使用真实世界的遗传数据集评估了16种两样本汇总水平MR方法,以提供最佳实践指南.我们的研究集中在以下几个关键方面:在存在各种混杂情况下的I型差错控制(例如,人口分层,多功能性,和家庭层面的混杂因素,如分类交配),因果效应估计的准确性,可复制性,和权力。通过综合评估一千个暴露-结果特征对的比较方法的性能,我们的研究不仅为比较方法的性能和局限性提供了有价值的见解,而且为研究人员选择合适的MR方法进行因果推断提供了实践指导.
    Mendelian randomization (MR), which utilizes genetic variants as instrumental variables (IVs), has gained popularity as a method for causal inference between phenotypes using genetic data. While efforts have been made to relax IV assumptions and develop new methods for causal inference in the presence of invalid IVs due to confounding, the reliability of MR methods in real-world applications remains uncertain. Instead of using simulated datasets, we conducted a benchmark study evaluating 16 two-sample summary-level MR methods using real-world genetic datasets to provide guidelines for the best practices. Our study focused on the following crucial aspects: type I error control in the presence of various confounding scenarios (e.g., population stratification, pleiotropy, and family-level confounders like assortative mating), the accuracy of causal effect estimates, replicability, and power. By comprehensively evaluating the performance of compared methods over one thousand exposure-outcome trait pairs, our study not only provides valuable insights into the performance and limitations of the compared methods but also offers practical guidance for researchers to choose appropriate MR methods for causal inference.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:全面的会议摘要使心理健康咨询具有有效的连续性,促进知情的治疗计划。然而,手动总结提出了一个重大挑战,将专家的注意力从核心咨询过程中转移开来。利用自动总结的进步来简化总结过程解决了这个问题,因为这使心理健康专业人员能够访问冗长的治疗会议的简明摘要,从而提高其效率。然而,现有的方法往往忽略了咨询互动中固有的细微差别的复杂性。
    目的:本研究通过基于方面的总结,评估了最先进的大型语言模型(LLM)在选择性总结治疗课程的各种组成部分方面的有效性,旨在衡量他们的表现。
    方法:我们首先创建了心理健康咨询-成分指导对话摘要,一个基准数据集,由191个咨询会议组成,摘要集中在3个不同的咨询组成部分(也称为咨询方面)。接下来,我们评估了11种最先进的LLM在解决咨询-成分指导总结任务方面的能力.使用标准摘要指标对生成的摘要进行定量评估,并由精神卫生专业人员进行定性验证。
    结果:我们的发现证明了特定任务的LLM的卓越性能,例如MentalLlama,米斯特拉尔,和MentalBART使用标准定量指标进行评估,如召回导向的激励评估(ROUGE)-1、ROUGE-2、ROUGE-L、和双向编码器表示从跨咨询组件的各个方面的变形金刚得分。此外,专家评估显示,Mistral在6个参数上取代了MentalLlama和MentalBART:情感态度,负担,伦理,连贯性,机会成本,和感知的有效性。然而,这些模型在机会成本和感知有效性指标的改进空间方面表现出共同的弱点。
    结论:虽然专门针对心理健康领域数据进行微调的LLM基于自动评估评分显示出更好的性能,专家评估表明,这些模型在临床应用中还不可靠。在实际实施之前,需要进一步完善和验证。
    BACKGROUND: Comprehensive session summaries enable effective continuity in mental health counseling, facilitating informed therapy planning. However, manual summarization presents a significant challenge, diverting experts\' attention from the core counseling process. Leveraging advances in automatic summarization to streamline the summarization process addresses this issue because this enables mental health professionals to access concise summaries of lengthy therapy sessions, thereby increasing their efficiency. However, existing approaches often overlook the nuanced intricacies inherent in counseling interactions.
    OBJECTIVE: This study evaluates the effectiveness of state-of-the-art large language models (LLMs) in selectively summarizing various components of therapy sessions through aspect-based summarization, aiming to benchmark their performance.
    METHODS: We first created Mental Health Counseling-Component-Guided Dialogue Summaries, a benchmarking data set that consists of 191 counseling sessions with summaries focused on 3 distinct counseling components (also known as counseling aspects). Next, we assessed the capabilities of 11 state-of-the-art LLMs in addressing the task of counseling-component-guided summarization. The generated summaries were evaluated quantitatively using standard summarization metrics and verified qualitatively by mental health professionals.
    RESULTS: Our findings demonstrated the superior performance of task-specific LLMs such as MentalLlama, Mistral, and MentalBART evaluated using standard quantitative metrics such as Recall-Oriented Understudy for Gisting Evaluation (ROUGE)-1, ROUGE-2, ROUGE-L, and Bidirectional Encoder Representations from Transformers Score across all aspects of the counseling components. Furthermore, expert evaluation revealed that Mistral superseded both MentalLlama and MentalBART across 6 parameters: affective attitude, burden, ethicality, coherence, opportunity costs, and perceived effectiveness. However, these models exhibit a common weakness in terms of room for improvement in the opportunity costs and perceived effectiveness metrics.
    CONCLUSIONS: While LLMs fine-tuned specifically on mental health domain data display better performance based on automatic evaluation scores, expert assessments indicate that these models are not yet reliable for clinical application. Further refinement and validation are necessary before their implementation in practice.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    将RNA-seq翻译成临床诊断需要确保检测临床相关的细微差异表达的可靠性和跨实验室一致性。例如不同疾病亚型或阶段之间的那些。作为四方项目的一部分,我们在45个实验室中,使用Quartet和MAQC参比样品掺入ERCC对照,进行了RNA-seq基准测试研究.基于多种类型的“地面实况”,我们系统地评估真实世界的RNA-seq性能,并调查涉及26个实验过程和140个生物信息学管道的影响因素。在这里,我们在检测四方样本之间的细微差异表达方面显示出更大的实验室间差异。实验因素包括mRNA富集和strandedness,每个生物信息学步骤,成为基因表达变异的主要来源。我们强调了实验执行的深远影响,并为实验设计提供最佳实践建议,过滤低表达基因的策略,以及最佳基因注释和分析管道。总之,本研究为临床诊断用RNA-seq的开发和质量控制奠定了基础。
    Translating RNA-seq into clinical diagnostics requires ensuring the reliability and cross-laboratory consistency of detecting clinically relevant subtle differential expressions, such as those between different disease subtypes or stages. As part of the Quartet project, we present an RNA-seq benchmarking study across 45 laboratories using the Quartet and MAQC reference samples spiked with ERCC controls. Based on multiple types of \'ground truth\', we systematically assess the real-world RNA-seq performance and investigate the influencing factors involved in 26 experimental processes and 140 bioinformatics pipelines. Here we show greater inter-laboratory variations in detecting subtle differential expressions among the Quartet samples. Experimental factors including mRNA enrichment and strandedness, and each bioinformatics step, emerge as primary sources of variations in gene expression. We underscore the profound influence of experimental execution, and provide best practice recommendations for experimental designs, strategies for filtering low-expression genes, and the optimal gene annotation and analysis pipelines. In summary, this study lays the foundation for developing and quality control of RNA-seq for clinical diagnostic purposes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Clinical Trial Protocol
    背景:澳大利亚偏远的原住民和托雷斯海峡岛民社区已经为健康商店启动了大胆的政策。基准,数据驱动和促进的“审计和反馈”与行动计划过程,提供了一个潜在的战略,以加强和扩大远程社区商店主管/所有者采用有利于健康的最佳实践。我们的目标是与五个合作伙伴组织共同设计基准模型,并与澳大利亚偏远地区的原住民和托雷斯海峡岛民社区商店测试其有效性。
    方法:研究设计是一项务实的随机对照试验,有同意的合格商店(位于澳大利亚非常偏远的北领地(NT),原住民社区的主要杂货店,并由营养从业者与研究伙伴组织提供服务)。基准模型是由研究证据提供的,专门构建的最佳实践审计和反馈工具,并与合作伙伴组织和社区代表共同设计。干预包括两个完整的基准周期(每年一个,2022/23和2023/24)评估,反馈,行动计划和行动实施。商店评估包括21个证据和行业知情的远程商店健康扶持政策的采纳状态,ii使用专门构建的StoreScout应用程序实施有利于健康的最佳实践,iii使用原住民和托雷斯海峡岛民健康饮食ASAP协议的标准化健康饮食的价格;和,使用销售数据指标的食品采购的健康度。合作伙伴组织反馈报告并与商店共同设计行动计划。控制商店接受评估并继续进行常规零售实践。所有商店都提供每周电子销售数据以评估主要结果,从所有购买的食品和饮料中游离糖(G)到能量(MJ)的变化,基线(2021年7月至12月)与2023年7月至12月。
    结论:我们假设基准干预措施可以改善对健康有利的商店政策和实践的采用,并减少澳大利亚偏远社区商店中不健康食品和饮料的销售。这项针对偏远原住民和托雷斯海峡岛民社区的创新研究可以为更广泛的健康食品零售提供有效的实施策略。
    背景:ACTRN12622000596707,协议版本1。
    BACKGROUND: Aboriginal and Torres Strait Islander communities in remote Australia have initiated bold policies for health-enabling stores. Benchmarking, a data-driven and facilitated \'audit and feedback\' with action planning process, provides a potential strategy to strengthen and scale health-enabling best-practice adoption by remote community store directors/owners. We aim to co-design a benchmarking model with five partner organisations and test its effectiveness with Aboriginal and Torres Strait Islander community stores in remote Australia.
    METHODS: Study design is a pragmatic randomised controlled trial with consenting eligible stores (located in very remote Northern Territory (NT) of Australia, primary grocery store for an Aboriginal community, and serviced by a Nutrition Practitioner with a study partner organisation). The Benchmarking model is informed by research evidence, purpose-built best-practice audit and feedback tools, and co-designed with partner organisation and community representatives. The intervention comprises two full benchmarking cycles (one per year, 2022/23 and 2023/24) of assessment, feedback, action planning and action implementation. Assessment of stores includes i adoption status of 21 evidence-and industry-informed health-enabling policies for remote stores, ii implementation of health-enabling best-practice using a purpose-built Store Scout App, iii price of a standardised healthy diet using the Aboriginal and Torres Strait Islander Healthy Diets ASAP protocol; and, iv healthiness of food purchasing using sales data indicators. Partner organisations feedback reports and co-design action plans with stores. Control stores receive assessments and continue with usual retail practice. All stores provide weekly electronic sales data to assess the primary outcome, change in free sugars (g) to energy (MJ) from all food and drinks purchased, baseline (July-December 2021) vs July-December 2023.
    CONCLUSIONS: We hypothesise that the benchmarking intervention can improve the adoption of health-enabling store policy and practice and reduce sales of unhealthy foods and drinks in remote community stores of Australia. This innovative research with remote Aboriginal and Torres Strait Islander communities can inform effective implementation strategies for healthy food retail more broadly.
    BACKGROUND: ACTRN12622000596707, Protocol version 1.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    冠状病毒病19大流行,由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,导致全球健康危机,数百万例确诊病例和相关死亡。SARS-CoV-2的主要蛋白酶(Mpro)对于病毒复制至关重要,并为药物开发提供了有吸引力的靶标。尽管某些药物获得批准,继续寻找有效的治疗方法。在这项研究中,我们系统地评估了Mpro的342个完整晶体结构,以确定基于结构的虚拟筛选(SBVS)的最佳构象。我们的分析表明,结构之间的结构灵活性有限。三个对接程序,AutoDockVina,rDock,和Glide被用来评估虚拟筛查的效率,揭示了选定的Mpro结构的不同表现。我们发现结构5RHE,7DDC,和7DPU(PDBIds)一致显示最低EF,AUC,和BEDROCK得分。此外,这些结构在所有对接程序中表现出最差的姿态预测结果。两个结构差异导致对接性能的变化:7DDC和7DPU中缺少S1子位点,并且在7DDC的S2子站点中存在一个子袋,7DPU,5RHE这些发现强调了为SBVS选择合适的Mpro构象的重要性,为推进药物发现工作提供有价值的见解。
    The coronavirus disease 19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global health crisis with millions of confirmed cases and related deaths. The main protease (Mpro) of SARS-CoV-2 is crucial for viral replication and presents an attractive target for drug development. Despite the approval of some drugs, the search for effective treatments continues. In this study, we systematically evaluated 342 holo-crystal structures of Mpro to identify optimal conformations for structure-based virtual screening (SBVS). Our analysis revealed limited structural flexibility among the structures. Three docking programs, AutoDock Vina, rDock, and Glide were employed to assess the efficiency of virtual screening, revealing diverse performances across selected Mpro structures. We found that the structures 5RHE, 7DDC, and 7DPU (PDB Ids) consistently displayed the lowest EF, AUC, and BEDROCK scores. Furthermore, these structures demonstrated the worst pose prediction results in all docking programs. Two structural differences contribute to variations in docking performance: the absence of the S1 subsite in 7DDC and 7DPU, and the presence of a subpocket in the S2 subsite of 7DDC, 7DPU, and 5RHE. These findings underscore the importance of selecting appropriate Mpro conformations for SBVS, providing valuable insights for advancing drug discovery efforts.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    在神经康复的背景下,基于传感器的量化肢体表现的临床工具得到了快速和持续的改进.由于评估程序中技术的日益整合,科学界已经出现了将循证医学与基准相结合的必要性。在这项工作中,我们提出了我们先前提出的关于上肢能力的基准测试方案在可重复性方面的实验验证,再现性,和临床意义。我们在记录运动学和肌电图的同时,对神经系统完整的年轻和老年受试者以及中风后患者进行了前瞻性多中心研究。60名受试者(30名年轻健康,15个健康的老人,和15中风后)完成了基准测试协议。该框架在不同的评估者和仪器之间是可重复的。年龄对健康受试者的计划绩效指标没有显着影响。在中风后的受试者中,运动呈现降低的平滑度和速度,运动幅度减小,肌肉激活显示较低的力量和较低的肢体内协调能力。我们修改了原来的框架,将其减少到三个运动技能,提取了14项有显著性的性能指标,与ARAT临床量表具有良好的相关性。该方案适用性广,它可能被认为是临床常规上肢功能评估的有价值的工具。
    In the context of neurorehabilitation, there have been rapid and continuous improvements in sensors-based clinical tools to quantify limb performance. As a result of the increasing integration of technologies in the assessment procedure, the need to integrate evidence-based medicine with benchmarking has emerged in the scientific community. In this work, we present the experimental validation of our previously proposed benchmarking scheme for upper limb capabilities in terms of repeatability, reproducibility, and clinical meaningfulness. We performed a prospective multicenter study on neurologically intact young and elderly subjects and post-stroke patients while recording kinematics and electromyography. 60 subjects (30 young healthy, 15 elderly healthy, and 15 post-stroke) completed the benchmarking protocol. The framework was repeatable among different assessors and instrumentation. Age did not significantly impact the performance indicators of the scheme for healthy subjects. In post-stroke subjects, the movements presented decreased smoothness and speed, the movement amplitude was reduced, and the muscular activation showed lower power and lower intra-limb coordination. We revised the original framework reducing it to three motor skills, and we extracted 14 significant performance indicators with a good correlation with the ARAT clinical scale. The applicability of the scheme is wide, and it may be considered a valuable tool for upper limb functional evaluation in the clinical routine.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号